Abbott announced on Thursday the launch of its over-the-counter continuous glucose monitor (CGM), Lingo, now available in the U.S. starting at $49. Lingo is designed for consumers seeking to understand how their bodies respond to food, exercise, sleep, and stress, making it one of the latest advancements in consumer-friendly biosensors.
Unlike CGMs traditionally used for managing diabetes, Lingo is aimed at adults who do not require insulin but wish to monitor and improve their overall health. By providing real-time glucose measurements through a sensor worn on the upper arm, Lingo offers insights into glucose fluctuations that, when consistently high, can lead to health issues such as metabolic disease, insulin resistance, and heart disease.
“The goal is not only to see what’s happening in your body but to help improve it and build healthy habits,” said Ben Fohner, director of Abbott’s Lingo app.
Abbott is targeting a new market with Lingo, as consumers without diabetes—particularly those with prediabetes—currently lack access to such tools unless prescribed. The company offers three pricing options: a single sensor for $49, two for $89, or six for $249, making it accessible to a wide range of users.
Abbott’s competitor, Dexcom, also entered the over-the-counter CGM market in August with its device, Stelo, available for $89 a month. Both companies are tapping into the growing prediabetes market, with around one in three Americans affected.
Lingo offers users real-time glucose data through a mobile app, including a “Lingo Count” metric, which assigns a numeric value to glucose spikes—sudden rises in blood sugar often triggered by eating. This unique feature allows users to monitor and minimize glucose spikes, helping to manage weight, improve sleep, and support overall health.
Olivier Ropars, Abbott’s divisional vice president of Lingo, emphasized the product’s value in fostering healthier habits, offering users a proactive approach to managing their health before developing chronic diseases.
Read More: Click Here
